Sanuwave Health Inc: (OTCBB: SNWV)
$0.70
-0.02 (-2.78%)
Volume 57,575
Jun 18 03:59 PM ET
Zacks Rank: NA 
| |
Overview Quote
Stock Activity
| Day Low - High | 0.67 - 0.72 |
| 52wk Low - High | 0.09 - 1.59 |
| Previous Close | 0.72 |
| Avg. Volume | 44,291 |
| Industry | MED PRODUCTS |
| Market Cap | 15.64 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.69 |
| P/E (F1) | 0.00 |
| Current Year Est. | -0.30 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
|
Zacks Recommendation
|
NA |
Zacks Industry Rank
|
178 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | NA |
| PEG Ratio | NA |
| Current Year Est. | -0.30 |
| Current Quarter Estimate | -0.10 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-07-2013 |
| EPS Last Year | -0.28 |
| Expected Earnings Growth | NA |
Company Description
SANUWAVE Health, Inc. is engaged in the development and commercialization of non-invasive, biological response-activating devices for the repair and regeneration of tissue, musculoskeletal and vascular structures. The Company's product candidates include its proprietary PACE technology applicable in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions; and dermaPACE for treatment of the skin and subcutaneous soft tissue. The Company's products help in activating biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration. SANUWAVE Health, Inc. is based in Alpharetta, USA.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.10 | -0.08 | -0.30 | -0.15 |
| Number of Estimates | 1 | 1 | 1 | 1 |
| Low Estimate | -0.10 | -0.08 | -0.30 | -0.15 |
| High Estimate | -0.10 | -0.08 | -0.30 | NA |
| Year Ago EPS | -0.07 | -0.07 | -0.30 | -0.30 |
| EPS Growth | -42.86% | -14.29% | 0.00% | 50.00% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| HAEMONETICS CP | HAE | 42.30 | |
|
| ATRICURE INC | ATRC | 9.19 | |
|
| BAXANO SURGICAL | BAXS | 2.30 | |
|
| CARDICA INC | CRDC | 1.15 | |
|
| INVIVO THERAPT | NVIV | 4.00 | |
|
| SHANDONG WEIGAO | SHWGF | 1.29 | |
|
| ABAXIS INC | ABAX | 46.65 | |
|
| ADVAXIS INC | ADXS | 0.04 | |
|
| BAXTER INTL | BAX | 70.73 | |
|
| BIOLIFE SOL INC | BLFS | 0.38 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
SNWV: $2MM Financing, CEO Hired
Feb 26, 2013
SNWV Raises Non-Dilutive Financing
Dec 04, 2012
SNWV: Q3 Results. Financing Update
Nov 19, 2012
SNWV: Q2 Results. Supplemental Trial On-Track
Aug 10, 2012
Report Not Available
Financials
| EPS TTM | -0.28 |
| Sales | 1 |
| Net Income | -10 |
| Price/Earnings | NA |
| Price/Book | NA |
| Price/Cash Flow | NA |
| Price/Sales | 21.40 |
News
SANUWAVE Announces Positive 24-Week Data from Its Pivotal Trial with dermaPACE for the Treatment of Diabetic Foot Ulcers - Benzinga
Jul 12, 2011
SANUWAVE Health Wins Patent Challenge - Comtex
Jun 14, 2011
Stockguru.com: SANUWAVE Health Inc. is in the StockGuru Spotlight for June 10, 2011 - Comtex
Jun 10, 2011
SANUWAVE Extracorporeal Shock Wave Technology Shown to Prevent and Repair Osteoarthritis Damage in Preclinical Model - Comtex
Jun 9, 2011
SANUWAVE Health Reports First Quarter Financial Results - Comtex
May 16, 2011
dermaPACE Pivotal Phase III Clinical Trial Results for Diabetic Foot Ulcer Treatment to Be Presented at the Symposium on Advanced Wound Care (SAWC) Spring 2011 - Comtex
Apr 12, 2011
SANUWAVE Health Secures $9.1 Million in Private Placement Funding - Comtex
Apr 7, 2011
SANUWAVE Health Secures $9.1 Million in Private Placement Funding - Comtex
Apr 7, 2011
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | 1.60 |
| Industry Rank by ABR | 178 out of 265 |
| Rank in Industry | 73 out of 72 |
